Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0.00 |
|
|||||
| News | - |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Edwards AG | AGE | NYSE | Ordinary Share |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | - |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| Trades | Volume | Avg Volume |
|---|---|---|
| 0 | 0.00 | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | USD |
Edwards AG Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 96.33M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
A G Edwards News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AGE Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00% |
A G Edwards Description
| AgeX Therapeutics Inc is a biotechnology company engaged in the development and commercialization of novel therapeutics targeting human aging. The firm through its PureStem and induced Tissue Regeneration (iTR) technologies develop innovative medicines designed to address some of the unsolved problems in aging. Its PureStem derived cell-based therapeutic candidates in development are AGEX-VASC1 and AGEX-BAT1. And iTR drug-based therapeutic candidates in development are AGEX-iTR1547 and Renelon. |
